Airship AI Holdings, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Airship AI Holdings, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.32M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $23.05M | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $12.30M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $14.55M | Apr 1, 2024 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.70M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $10.53M | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $5.76M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $8.42M | Apr 1, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $29.32M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | ($57.46M) | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $16.37M | Feb 28, 2025 |
| FY2023 | Dec 21, 2023 | $16.37M | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | ($487.5K) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $5.02M | Mar 31, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.22M) | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | ($3.51M) | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | ($6.64M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | ($2.82M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($1.02M) | Mar 31, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.08M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $2.80M | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $2.73M | Feb 28, 2025 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.84M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $11.23M | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $9.68M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $7.63M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $100.0K | Mar 31, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($8.00M) | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | ($6.50M) | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | ($3.29M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | ($2.90M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($1.55M) | Mar 31, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.48M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $13.71M | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $6.09M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $3.91M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $326.07M | Mar 31, 2023 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $26.62M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $66.73M | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $23.58M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $12.27M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $20.39M | Mar 31, 2023 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.15M) | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | ($53.02M) | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | ($17.49M) | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | ($8.36M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | ($8.41M) | Apr 1, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($45.62M) | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | ($74.94M) | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | ($17.48M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | ($10.31M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($18.01M) | Mar 31, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.75M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $11.41M | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $3.12M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $298.6K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $1.66M | Mar 31, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | 1 | Feb 28, 2025 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Feb 28, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 34.37M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | 30.59M | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | 22.81M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | 13.39M | Apr 1, 2024 |